by Chelsea Dye
I get asked all the time what supplements someone should be taking. And I have to laugh sometimes, because the question usually arrives while the person is sitting on the couch, eating ultra-processed food, sleeping five hours a night, and pouring a glass of wine — every night — expecting the capsule to be the thing that makes it all okay.
I understand the appeal. I really do. A supplement is simple. It’s a decision you make once, at the pharmacy or on Amazon, and then it’s handled. Sleep, movement, food, connection — those aren’t one-time decisions. They’re the same decision, made over and over, every single day, often when you’re tired and don’t feel like making it. Of course the pill is more appealing. It’s the easier ask.
But it’s not a get-out-of-jail-free card. There isn’t one of those — except in Monopoly.
The industry that’s supposed to have the answer doesn’t even agree on the question
Here’s something that might surprise you: the people running the wellness industry can’t agree on how big it even is. Depending on who you ask, global wellness spending is somewhere between $4.8 trillion and $6.8 trillion a year. If the experts can’t agree on how to measure wellness, it makes sense that the rest of us are confused about what actually works.
And the supplement aisle specifically — that $60+ billion slice of the industry — runs almost entirely on the honor system. Under a law from 1994, supplements are regulated as food, not drugs. No one has to prove a product works, or is even safe, before it hits the shelf. The burden of proof only shows up after something goes wrong. Third-party testing exists, but it’s optional, and most people have no idea whether the bottle in their cabinet ever went through it.
Layer on top of that the fact that AI chatbot misuse was just named the single biggest health technology hazard of the year — ahead of hospital equipment — and that nearly half of AI-generated health answers in a recent audit were rated problematic, with one in five flagged as seriously misleading. Meanwhile, the generation most likely to trust TikTok and YouTube for health advice is the same generation least likely to be getting that advice from an actual clinician.
So: a massive, unregulated, honor-system industry. A generation increasingly getting its health information from an algorithm instead of a person. And somewhere underneath all of that noise, the boring stuff — the stuff that actually moves the needle — is sitting almost completely untouched.
- Sleep: Roughly 3 in 10 adults get less than 7 hours a night.
- Movement: Only about 1 in 5 adults meet the full combined aerobic and strength-training guidelines. Four out of five of us are falling short.
- Fiber: About 5% of American adults hit their daily fiber target. Not 50%. Five.
Those three things — sleep, movement, fiber — are some of the most well-evidenced levers in all of health. And they’re the most neglected part of the entire conversation.
The GLP-1 parallel nobody wants to say out loud
I’ve been thinking about this a lot lately, because I see the exact same psychology showing up in a completely different, much more powerful tool: GLP-1 medications.
I want to be clear about something first — GLP-1s are a legitimate, sometimes life-saving medical tool. For a lot of people, they’ve meaningfully changed the trajectory of their health, and I’m not interested in being part of the pile-on that treats them as a moral failing or a shortcut. They’re a real medication, doing a real thing, in real bodies.
But here’s where the parallel gets interesting to me: the data is starting to show that GLP-1s are being treated the exact same way as that magic supplement bottle — as if the medication alone is the whole intervention, rather than one part of it.
A study presented at this year’s Endocrine Society meeting tracked real-world activity data from people starting GLP-1 medications and found something the researchers called out directly: physical activity decreased after starting the medication. Daily steps dropped. Minutes of moderate-to-vigorous activity dropped. And the assumption that weight loss would naturally lead to more movement — turned out to be wrong. It didn’t happen. The researchers were blunt about it: exercise cannot be optional for people on these medications, because the drugs reduce lean muscle mass along with fat, and without resistance training and adequate protein, you’re not just losing weight — you’re losing the muscle that keeps you strong, mobile, and metabolically healthy long-term.
And then there’s what happens when people stop. The numbers here are sobering. In one major trial extension, people who discontinued semaglutide regained about two-thirds of the weight they’d lost within a year. A separate meta-analysis of GLP-1 discontinuation found an average regain of over 5% of body weight, along with a reversal of the blood sugar, blood pressure, and cholesterol improvements the medication had produced. The weight comes back. So does the risk.
The medication isn’t the failure point in either of those findings. The failure point is the same one hiding underneath the supplement conversation: the belief that the intervention itself is the whole plan, instead of one part of a plan that still requires sleep, movement, protein, and food quality to actually hold.
There’s actual evidence for this, not just my opinion. In trials where GLP-1 medication was paired with supervised strength and aerobic training and adequate protein intake, people didn’t just lose weight — they gained lean muscle mass, something that essentially never happens with the medication alone. And it’s not just exercise — clinical experts presenting at this year’s ADA conference cited evidence that involving a registered dietitian alongside GLP-1 treatment can cut medication discontinuation rates by 5 to 10% in trials, and likely more in real-world practice. The tool works better, and more durably, when it’s not carrying the whole plan by itself.
That’s the same story as the supplement drawer. That’s the same story as the wine and the couch and the ultra-processed dinner. The tool isn’t the problem. The belief that the tool gets you out of doing the rest of it — that’s the problem.
The one-line version
The wellness industry has never been bigger, louder, or more confusing. And the things that actually work — sleep, movement, real food, connection — are the most neglected part of the entire conversation, whether we’re talking about a $40 bottle of berberine or a $1,000-a-month injection.
There’s no capsule, no injection, no protocol that replaces the fundamentals. They’re not the boring backup plan. They’re the whole plan. Everything else — the supplement, the medication, the fancy protocol — works with that foundation, not instead of it.
No get-out-of-jail-free card. Except in Monopoly.
Shine bright and step into the light,
Chelsea
Chelsea Dye is a certified lifestyle medicine coach, wellness strategist, founder of Alchemist Untamed, co-founder of Purpose & Plants, and speaker.
Sources: Global Wellness Institute (2025) · DSHEA/FDA regulatory overview · ECRI 2026 Top 10 Health Technology Hazards · Tiller et al., BMJ Open (2026) · KFF Tracking Poll on Health Information and Trust (Aug 2025) · CDC/NCHS Data Briefs No. 555 & 559 (Apr 2026) · Stanford Medicine (June 2026) · Endocrine Society, ENDO 2026 (Maharjan et al.) · STEP-1 extension trial · Lancet eClinicalMedicine meta-analysis on GLP-1 discontinuation (2025) · AJMC, “GLP-1 Therapies in 2026” (2026 ADA coverage)